PETHEMA Foundation: Leukemia, Myeloid, Acute trials

The registry lists 22 Leukemia, Myeloid, Acute studies with PETHEMA Foundation as lead sponsor. 1 are open to participants now and 0 have results posted.

Phase 1 6Phase 2 8Phase 3 3Phase 4 5No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)RecruitingNCT07478991Phase 3
• A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic MarkersCompletedNCT05541224
• Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years OldCompletedNCT04687761Phase 1/2
• Molecular Diagnostic Platform for AMLStatus unknownNCT04446741
• A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First TreatmentStatus unknownNCT04112589Phase 1/2
• Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)CompletedNCT04107727Phase 2
• Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard ChemotherapyActive, not recruitingNCT04090736Phase 3
• Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AMLCompletedNCT03661515Phase 1
• Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.CompletedNCT03311815
• Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02319135Phase 3
• Treatment of Relapsed or Refractory Acute Myeloblastic LeukemiaCompletedNCT01435343Phase 1/2
• PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 YearsStatus unknownNCT01296178Not applicable
• LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)TerminatedNCT01198054Phase 4
• Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 YearsTerminatedNCT01193400Phase 2
• LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)CompletedNCT01041040Phase 4
• Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)CompletedNCT00840346Phase 1/2
• Velcaflagida in Relapsed or Refractary Acute Myeloid LeukemiaCompletedNCT00651781Phase 1/2
• Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00488709Phase 4
• SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic LeukemiaCompletedNCT00487448Phase 4
• Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 YearsCompletedNCT00464217Phase 4
• Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary AspergillosisCompletedNCT00391014Phase 2
• Treatment of Acute Myeloblastic Leukemia in Younger PatientsCompletedNCT00390715